philipn / TRV027 71e6944ff5e225c2ef8b20452cafb8417db505cd

Create Draft
Adding image, more detail
Review changes View this version of the page
You can also use the and keys
Deletions are marked like this Additions are marked like this

TRV027 is a biased agonist of the AT1 receptor currently in development by Trevena, Inc.  It is being trialed as a drug to treat COVID-19.

See also
The chemical structure of TRV027.

TRV027 is an antagonist AT1 receptor currently in development by Trevena, Inc.  It is being trialed as a drug to treat COVID-19.  TRV027 is given as an intravenous infusion.

TRV027 is a synthetic analogue of Angiotensin II.  The CAS# of TRV027 is 1234510-46-3.

See also
Create Draft
Contributed by
Except where otherwise noted, text content is licensed under a Creative Commons Attribution-ShareAlike License. See copyright information.